Covid-19: Pfizer and BioNTech vaccines ‘were more than 90% effective’

The first coronavirus vaccine was available to prevent the disease in more than 90% of vaccinated people, according to a preliminary analysis.

The vaccine’s makers, Pfizer and BioNTech, call it “a great day for science and humanity.”

The vaccines of the two brands have been tested in 43,500 people in six countries and do not pose any safety concerns.

The companies plan to request urgent approval for the vaccine to be available for use by the end of the month.

An effective vaccine combined with more effective therapies is considered to be the best way to get rid of the limitations that are being applied in our lives today.

There are currently about 10 vaccines in the final testing phase, called the third testing phase, but this is the first vaccine to work.

The vaccine uses an injection of part of the virus’s genetic code to train the body’s immune system.

Previous tests showed that the vaccine trains the body, produces antibodies and another part of the immune system, called T cells, to fight the corona virus.

The vaccine should be given in two doses, 3 weeks apart.

Trials conducted in the United States, Germany, Brazil, Argentina, South Africa, and Turkey showed that 90% of those injected developed protection within seven days after the second dose.

The UK will have 10 million doses by the end of this year and another 30 million more orders.

However, there are logistical challenges, as vaccines must be stored in extremely cold conditions, as low as -80 degrees Celsius.

There are also questions about how long the immunity will last and how effective the vaccine is for different age groups.

This positive preliminary information means that the American pharmaceutical giant and its German counterpart are at the forefront of the vaccine race, having signed prior agreements with governments around the world. it is intended to provide hundreds of millions of doses.

Pfizer believes it has the capacity to deliver 50 million doses by the end of this year and about 1.3 billion doses by the end of 2021.

Pfizer shares rose sharply in the session before the official market opening, 15%, while the US firm BioNtech rose a%.

The news also caused the MSCI All Country World Index to increase in value by another $ 500 billion.